Vir Biotechnology Appoints Timothy Coughlin to Board of Directors Amid Pipeline Advancement
Key Insights
Vir Biotechnology appointed Timothy Coughlin, former CFO of Neurocrine Biosciences, to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026.
Coughlin brings extensive experience guiding companies from clinical-stage to fully integrated commercial enterprises, including navigating regulatory setbacks.
The appointment comes as Vir advances its potential best-in-class treatment for chronic hepatitis delta (search) and its pipeline of masked T-cell engagers for solid tumors (search).
Vir Biotechnology, Inc. (Nasdaq: VIR) announced on June 10, 2026, the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. The appointment arrives at what CEO Marianne De Backer described as "a pivotal moment for the company," as the clinical-stage biopharmaceutical firm advances its portfolio of investigational therapies for infectious diseases and cancer.
De Backer, M.Sc., Ph.D., MBA, emphasized the strategic value Coughlin brings to the organization. "Tim brings a strong background of strategic discipline and operational insight that has helped organizations evolve into fully integrated enterprises," she stated. "His extensive experience as chief financial officer and board member spanning discovery through commercialization will be highly valuable as we advance our portfolio."
Coughlin's track record includes serving as Chief Financial Officer of Neurocrine Biosciences, Inc., where he helped lead the company's transition from a clinical-stage biotechnology company to a fully integrated commercial pharmaceutical company. Notably, this transformation occurred after the company navigated a key regulatory setback, ultimately bringing important therapies to patients while increasing shareholder value.
"I am excited to join the Board of Directors at Vir Biotechnology and contribute to the advancement of the company's potential best-in-class treatment regimen for hepatitis delta (search) and the progression of its robust pipeline of masked T-cell engagers for solid tumors (search)," said Coughlin. "Vir Biotechnology is poised to make a meaningful difference for patients, and I look forward to supporting that impact."
Prior to Neurocrine, Coughlin served as Vice President of Financial Services at Catholic Health Initiatives, a nationwide integrated healthcare delivery system, and as a Senior Manager in the Health Sciences practice of Ernst & Young LLP.
Coughlin currently holds board positions at several biopharmaceutical companies, serving as chair of the board of directors of aTyr Pharma, Inc. and as a member of the boards of ADC Therapeutics SA and Travere Therapeutics, Inc. His previous board service includes Fate Therapeutics, Inc. (search) and Peloton Therapeutics, Inc., the latter prior to its acquisition by Merck (search) in 2019.
Coughlin holds a master's degree in international business from San Diego State University and a bachelor's degree in accounting from Temple University. He is a certified public accountant in both California and Pennsylvania.
Vir Biotechnology is a clinical-stage biopharmaceutical company focused on powering the immune system to discover and develop medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta (search) and multiple PRO-XTEN dual-masked T-cell engagers across validated targets in solid tumor indications. The company also maintains a preclinical portfolio spanning infectious diseases and oncologic malignancies. Vir Biotechnology holds exclusive rights to the universal PRO-XTEN masking platform for oncology and infectious disease, a technology trademarked by Amunix Pharmaceuticals, Inc., a Sanofi company.